2009-11-02 14:47:03 -

Regulatory News.

Meda’s (STO:MEDAA) partner for Retigabine, Valeant Pharmaceuticals, today announced that Retigabine completed both the New Drug Application (NDA) and the Marketing Authorisation Application (MAA) submissions on October 30, 2009.

Retigabine comprises a new way of affecting potassium channels in the central nervous system. It has been documented to treat epilepsy and has a different mechanism of action compared to current antiepileptic therapies.

The pharmaceutical company GlaxoSmithKline has signed a worldwide collaboration agreement with Valeant Pharmaceuticals for the Retigabine substance. Meda is entitled to receive significant royalties and certain milestone payments on the Retigabine substance.

MEDA AB (publ) is a leading international specialty pharma company.

Meda’s products are sold in 120 countries worldwide and

the company is represented by its own organizations in more than 40 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se : .

This information was brought to you by Cision www.cisionwire.com :

MEDA ABAnders Larnholt, Vice President Corporate Development & IRTelephone:

+46 709-458 878